The United Kingdom Prospective Diabetes Study (UKPDS)
This was a large study published in September 1998 in The Lancet and in the British Medical Journal. It had over 5000 patients and a mean follow up of 10 years. The main questions that this study answered were

1. Does good control of blood sugar with pharmacological treatment give any clinical benefit to patients with Type 2 diabetes?

2. Are there any specific benefits associated with sulphonylureas, metformin or insulin in these patients?

The lessons we have learnt from this study are:

a. There is a significant decrease in the microvascular complications of diabetes (eye, kidney and nerves) with better control of blood sugar and Sulphonylureas, Metformin and Insulin are all equally effective in reducing the incidence of microvascular complications provided there is adequate control of blood sugar. (Reference: The Lancet)

b. Metformin is better than sulphonylureas or insulin in overweight patients with Type 2 diabetes. (Reference: The Lancet)

c. In order to achieve a clinically important reduction in diabetes related deaths, it is necessary to control blood pressure as well as blood sugar. (Reference: British Medical Journal

Unless otherwise stated, the content of this page is licensed under Creative Commons Attribution-ShareAlike 3.0 License